Syndax Pharmaceuticals, Inc. SNDX
9.49 USD -0.06 (-0.63%)
At closeNov 10, 2026, 4:00 PM EST
9.49 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
9.29 Day range 9.87
9.15 52-week range 25.59
- YTD
- -54.83%
- 1 year
- -39.63%
News
globenewswire.com Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
seekingalpha.com Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key Syndax Pharmaceuticals remains on track, with Revuforj driving robust commercial growth and Niktimvo providing a secondary revenue stream. 3Q26 revenue surged 82% YoY to $83.3M, led by Revuforj's 90%…
globenewswire.com Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company…
globenewswire.com Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 – 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (“Syndax” or the “Company”) (NASDAQ: SNDX). Such investors are…
benzinga.com Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
benzinga.com HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $36.
benzinga.com Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 21.43 percent increase over…
benzinga.com Syndax Pharmaceuticals Suffers Pipeline Blow Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
benzinga.com Crude Oil Edges Higher; Citigroup Earnings Top Views U.S. stocks edged lower; Citi beat Q3 estimates. Bumble and BIO-key surged, while Pershing Square, Cipher Digital and Syndax fell.
benzinga.com Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.- benzinga.com HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
benzinga.com Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket UnitedHealth rose after Q3 earnings and sales beat estimates; BIO-Key led gainers, while HUB Cyber Security topped premarket losers.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33 UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
benzinga.com JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40 JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
benzinga.com HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.
benzinga.com Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 33.73 percent increase over…- benzinga.com HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
benzinga.com Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 Congress – Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –– Ph 1 trial of revumenib with…- benzinga.com Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical Oncology – High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –– Strong activity across…
benzinga.com Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026 – Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of…- benzinga.com Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.
- benzinga.com Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026 – Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –– Data underscoring…
- benzinga.com UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37 UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $37.
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Earnings Scheduled For November 3, 2025 
benzinga.com Earnings Scheduled For August 4, 2025 
benzinga.com Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Earnings Scheduled For May 5, 2025
benzinga.com NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For March 3, 2025
- benzinga.com Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- benzinga.com Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session.